# Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis

> **NCT01014546** · PHASE1 · TERMINATED · sponsor: **Roswell Park Cancer Institute** · enrollment: 5 (actual)

## Conditions studied

- Essential Thrombocythemia
- Polycythemia Vera
- Primary Myelofibrosis

## Interventions

- **DRUG:** Arsenic Trioxide
- **DIETARY_SUPPLEMENT:** Ascorbic Acid
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT01014546
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-04
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2022-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01014546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01014546, "Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01014546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*